India is increasingly being recognized as a significant player in the biosimilar immunotherapy sector, driven by a growing demand for affordable cancer treatment options. The country's market potential is bolstered by a favorable regulatory environment and a rising number of pharmaceutical companies investing in biosimilars. However, oncologists have noted that patient awareness regarding these therapies remains insufficient, which could hinder broader adoption. Despite the advancements in drug development and the potential cost savings associated with biosimilars, many patients are still unfamiliar with the benefits and availability of these treatments. This gap in knowledge presents a challenge for healthcare providers and industry stakeholders as they aim to educate patients and increase the uptake of biosimilar immunotherapies in a market that is poised for growth.